-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $20

Benzinga·11/11/2026 14:37:36
Listen to the news
Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $25 to $20.